Active substanceFlutamideFlutamide
Similar drugsTo uncover
  • Flutamide
    pills inwards 
    AKTAVIS GROUP, AO     Iceland
  • Flutamide
    pills inwards 
    MEDINTORG, ZAO     Russia
  • Flutamide
    pills inwards 
    Orion Corporation     Finland
  • Flutamide
    pills inwards 
  • Flutamide
    pills inwards 
    ATOLL, LLC     Russia
  • Flutamide Pliva
    pills inwards 
  • Flutamide Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Flutamide STADA®
    pills inwards 
  • Flutamide-TL
    pills inwards 
  • Flutaplex
    pills inwards 
  • Flucin®
    pills inwards 
  • Dosage form: & nbsppills
    Composition:
    1 tablet contains:
    Active substance: flutamide - 250.0 mg;
    Excipients: lactose anhydrous - 221.7 mg, sodium lauryl sulfate - 15.0 mg, microcrystalline cellulose - 100.0 mg, pregelatinized starch - 162.5 mg, silicon dioxide - 0.4 mg, magnesium stearate - 0.4 mg .

    Description:
    Round biconvex tablets of light yellow color with a risk on one side and engraving "SP" on the other side.

    Pharmacotherapeutic group:Antitumor agent, antiandrogen.
    ATX: & nbsp

    L.02.B.B.01   Flutamide

    Pharmacodynamics:
    Flutamide is a non-steroidal antiandrogenic, antitumor drug. Competitively blocks the interaction of androgens with their cellular receptors. The mechanism of action is based on inhibition of androgen uptake and / or inhibition of androgen binding in target cell nuclei. Its ability to inhibit the action of testosterone at the cellular level is in addition to the drug "castration" caused by gonadotropin-releasing hormone (GnRH) agonists. The target organs of the pharmacological action of flugamide are the prostate gland and seminal vesicles. Flutamide does not possess estrogenic, antiestrogenic, progestogen and anti-gestagenic activity.

    Pharmacokinetics:
    When ingested, the drug is fully and rapidly absorbed, undergoing biotransformation in the liver to form a biologically active a-hydroxylated derivative (2-hydroxy-flutamide). The time to reach the maximum concentration of active metabolite is 2 hours, the connection with proteins is 94-96%. From the body the drug is excreted mainly by the kidneys. About 4.2% is secreted through the intestine within 72 hours.The half-life of the active metabolite from the plasma is about 6 hours (in elderly patients - 8 hours after a single dose and 9.6 hours at a stable concentration). After repeated administration of flutamide 250 mg three times a day, a stable level of drug concentration and its active metabolite in plasma was achieved after a fourth dose of flutamide.

    Indications:
    Treatment of metastatic prostate cancer when suppression of testosterone is indicated:
    • at the beginning of treatment in combination with GnRH agonists;
    • as an additional treatment for patients already receiving therapy with HNRH agonists;
    • in patients with surgical castration;
    • treatment of patients in whom other types of hormone therapy were ineffective - or with intolerance of such treatment.

    Contraindications:
    • hypersensitivity to flutamide or other components of the drug;
    • severe hepatic impairment;
    • childhood.

    Carefully:
    • abnormal liver function;
    • propensity to thrombosis;
    • concomitant cardiovascular diseases;
    • states predisposing to intoxication aniline (one of the metabolites flutamide - methylaniline derivative): deficiency of glucose-6-phosphate dehydrogenase, smoking, hemoglobinopathy (M-hemoglobin).

    Dosing and Administration:
    Inside, 250 mg 3 times a day - every 8 hours.
    In case of achieving a positive effect, the drug is used until signs of progression of the tumor develop.
    When combined therapy with GnRH agonists, both drugs can be administered concomitantly, or Flucin® is administered 24 hours before the first admission of the GnRH agonist.
    In the appointment of radiation therapy, the preparation Flucin® is prescribed 8 weeks before the beginning of the treatment and the preparation of the preparation Flucin® is continued for the entire duration of radiation therapy.

    Side effects:
    With monotherapy. The most common adverse events are gynaecomastia and / or pain in the thoracic glands, sometimes accompanied by galactorrhea. These phenomena disappear upon discontinuation or after a dose reduction. Less frequent diarrhea, nausea, vomiting, increased appetite, insomnia, fatigue, transient liver dysfunction, hepatitis.
    In rare cases, the following side effects are noted: decreased libido, gastrointestinal disturbances (lack of appetite, heartburn, constipation, pain similar to stomach ulcer pain), peripheral edema,subcutaneous hemorrhage, shingles, itching, lupus-like syndrome, headache, dizziness, weakness, visual acuity, thirst, chest pain, anxiety, depression, lymphangiectatic edema, change in urine color (from amber to yellow-green). With prolonged treatment, suppression of spermatogenesis was noted.
    The following spontaneous side effects were also noted: hemolytic anemia, macrocytic anemia, methemoglobinemia, sulfemoglobinemia, increased photosensitivity reactions (including erythema, ulceration, bullous rash, epidermal necrolysis), obstructive jaundice, hepatic encephalopathy, liver necrosis, increased urea nitrogen and creatinine levels. These side effects usually occur after discontinuation of therapy. However, there are reports of a fatal outcome due to severe liver damage caused by the administration of flutamide. Very rarely there is hyperglycemia and exacerbation of diabetes mellitus.
    When treated in combination with GnRH agonists. Most often, "hot flashes" (fever, sweating), decreased libido, impotence, diarrhea, nausea, vomiting are possible.The incidence of these side effects, with the exception of diarrhea (more pronounced when used in conjunction with flutamide), is the same as with monotherapy with GnRH agonists. The incidence of gynecomastia with combination therapy is significantly lower than in monotherapy, and is comparable to the incidence of placebo.
    Rarely, the following side effects may occur: anemia, leukopenia, thrombocytopenia, gastrointestinal disorders of unclear etiology, lack of appetite, peripheral edema, symptoms of neuromuscular disorders, jaundice, symptoms of genitourinary system disorders, increased blood pressure and side effects from the central nervous system (drowsiness, depression, confusion, anxiety, neurosis). In very rare cases, interstitial lung diseases, hepatitis, and increased photosensitivity may occur.

    Overdose:
    In clinical trials conducted using dosages of up to 1500 mg per day for up to 36 weeks, no serious side effects have been reported.Registered side effects included gynecomastia, breast tenderness and a slight increase in activity of aspartate aminotransferase.
    If the patient is conscious and without spontaneous vomiting, you should induce vomiting. Possible gastric lavage. It is necessary to apply symptomatic therapy with constant monitoring of vital functions. Hemodialysis is ineffective due to the high degree of binding of the drug to proteins.

    Interaction:
    In view of the possible enhancement of the anticoagulant effect with simultaneous use of indirect anticoagulants (eg, warfarin) and flutamide, a dose of anticoagulant should be selected under the control of prothrombin time.
    With the combined use of theophylline and flutamide, the concentration of deophylline in the blood can increase.

    Special instructions:
    Treatment should be carried out under the control of the activity of "hepatic" enzymes in the blood once a month for the first 4 months and then regularly every month.
    In the case of increased activity of liver enzymes 2-3 times in comparison with the upper limit of normal values ​​and / or the appearance of jaundice in the absence of metastases in the liver, the use of Flucin® should be stopped.
    Patients should receive a recommendation to immediately consult a doctor when the first symptoms of liver dysfunction occur, such as pruritus, darkening of the urine, nausea, vomiting, persistent loss of appetite, icterus of the skin or sclera, pain in the right hypochondrium or influenza-like symptoms.
    Effect on the ability to drive transp. cf. and fur:
    Effects of the drug on the ability to drive and other mechanisms are not identified.

    Form release / dosage:
    Tablets of 250 mg.
    Packaging:
    For 10 or 20 tablets in a blister, made of PVC and aluminum foil. 5 (20 tablets each) and 10 (10 tablets) of blisters together with instructions for use are placed in a cardboard pack.

    Storage conditions:
    Store at a temperature not exceeding 25 ° C.
    Keep out of the reach of children.

    Shelf life:
    5 years. Do not use the drug after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N012620 / 01
    Date of registration:26.03.2011
    Date of cancellation:2016-03-11
    The owner of the registration certificate:MSD FARMASYUTIKALS, LLC MSD FARMASYUTIKALS, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspMSD Pharmaceuticals Ltd.MSD Pharmaceuticals Ltd.
    Information update date: & nbsp22.10.2015
    Illustrated instructions
      Instructions
      Up